Monika Licaj, Rana Mhaidly, Yann Kieffer, Hugo Croizer, Claire Bonneau, Arnaud Meng, Lounes Djerroudi, Kevin Mujangi-Ebeka, Hocine R Hocine, Brigitte Bourachot, Ilaria Magagna, Renaud Leclere, Lea Guyonnet, Mylene Bohec, Coralie Guérin, Sylvain Baulande, Maud Kamal, Christophe Le Tourneau, Fabrice Lecuru, Véronique Becette, Roman Rouzier, Anne Vincent-Salomon, Geraldine Gentric, Fatima Mechta-Grigoriou
Although cancer-associated fibroblast (CAF) heterogeneity is well-established, the impact of chemotherapy on CAF populations remains poorly understood. Here we address this question in high-grade serous ovarian cancer (HGSOC), in which we previously identified 4 CAF populations. While the global content in stroma increases in HGSOC after chemotherapy, the proportion of FAP+ CAF (also called CAF-S1) decreases. Still, maintenance of high residual CAF-S1 content after chemotherapy is associated with reduced CD8+ T lymphocyte density and poor patient prognosis, emphasizing the importance of CAF-S1 reduction upon treatment...
February 12, 2024: Nature Communications